24/7 Market News Snapshot 08 May, 2025 – Novavax Inc (NASDAQ:NVAX)

May 8, 2025

DENVER, Colo., 08 May, 2025 (www.247marketnews.com) – (NASDAQ:NVAX) are discussed in this article.
Novavax Inc (NVAX) has experienced a significant surge in its stock price, trading at approximately $7.93, marking an impressive increase of 33.24% from the previous day’s close of $5.95. This upward movement, seen in pre-market trading with a robust volume of nearly 2.94 million shares, reflects a renewed investor optimism. The excitement surrounding Novavax appears to be fueled by its recent operational advancements and promising financial results.

In the first quarter of 2025, Novavax reported remarkable revenue growth, achieving $667 million, a stark increase from $94 million in the same quarter last year. This surge was largely driven by additional revenue from Advance Purchase Agreements linked to its COVID-19 vaccine, Nuvaxovid®, with around $603 million recognized from previous years. John C. Jacobs, President and CEO, emphasized the company’s commitment to enhancing corporate growth and shareholder value through strategic partnerships and innovation.

The company aims to optimize its collaboration with Sanofi, focusing on leveraging its cutting-edge technology platform and advancing its early-stage pipeline. Encouraging feedback from the U.S. Food and Drug Administration regarding its Biologics License Application (BLA) hints at a favorable approval trajectory, contingent on agreement on post-marketing study parameters. Such approval could unlock milestone payments from Sanofi, starting with an anticipated $175 million upon acceptance.

Furthermore, preliminary results from the SHIELD-Utah study indicated that individuals administered with Nuvaxovid® experienced approximately 39% fewer and less severe side effects compared to existing mRNA vaccines, reinforcing the vaccine’s competitive edge. In light of these developments, Novavax has raised its revenue forecast for 2025 to between $975 million and $1.025 billion, underscoring its optimism for sustainable growth and impact in addressing global health challenges.

Related news for (NVAX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.